Cognitive Impairment Assessment Using Multi-Biomarker Index Values
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining cognitive impairment or cognitive decline are not accurate enough, as they rely on measuring single specific proteins or oligopeptides in blood, which may not provide a comprehensive understanding of the condition.
Innovation Solution
A method that calculates index values based on the amounts of two or more biomarkers in a biological sample, generating supporting information to accurately determine cognitive impairment, cognitive decline, or the risk of either, and providing insights into related conditions such as nutritional, lipid metabolism, inflammatory, and vascular statuses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single specific protein or oligopeptide measurement is used, then the measurement process is simple, but the diagnostic accuracy for cognitive impairment is insufficient
Solution Approach 1:
The patent combines measurements of multiple biomarkers (apolipoprotein A1, transthyretin, complement C3, and other proteins/oligopeptides) into a single comprehensive diagnostic assessment. By merging these multiple measurement results and analyzing them together, the system achieves higher diagnostic accuracy for cognitive impairment while managing the complexity through integrated processing.
Solution Approach 2:
The patent uses a composite biomarker profile consisting of multiple different proteins and oligopeptides rather than relying on a single biomarker. This composite approach combines information from apolipoprotein A1, transthyretin, complement C3, and other substances to create a more accurate diagnostic picture, similar to how composite materials combine different properties to achieve superior performance.
2Measurement precision
If multiple biomarkers are measured, then the diagnostic accuracy improves, but the complexity of analysis increases
Solution Approach 1:
The patent introduces an information processing device that acts as an intermediary between the multiple biomarker measurements and the diagnostic conclusion. This device automatically integrates the measurement data from various biomarkers, performs the necessary calculations, and generates the diagnostic result, thereby reducing the analytical difficulty for clinicians while maintaining high determination accuracy.
Solution Approach 2:
The patent creates a multi-functional diagnostic system that simultaneously evaluates multiple biomarkers (proteins and oligopeptides) and generates comprehensive diagnostic information for cognitive impairment. The system performs multiple functions including measuring different biomarker types, integrating their results, and providing unified diagnostic assessment, thereby managing analysis complexity through universal processing.
3Loss of information
If comprehensive biomarker analysis is performed, then understanding of related conditions (nutritional, lipid metabolism, inflammatory, vascular status) improves, but the time and resources required increase
Solution Approach 1:
The patent performs preliminary analysis by measuring multiple biomarkers simultaneously and pre-processing their relationships. The system prepares comprehensive information about nutritional status, lipid metabolism, inflammatory status, and vascular status in advance by analyzing the biomarker profile, so that when diagnostic needs arise, the information is already integrated and ready for interpretation, reducing the time required at the point of diagnosis.
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
[Problems] The purpose of the present technology is to provide a technique for accurately determining cognitive impairment, cognitive decline, or risk of any of them. [Solution] The present technology provides a determination supporting information generating method, comprising: an index value calculating step of calculating, based on amounts of two or more biomarkers contained in a biological sample derived from a human, (I) a first index value indicating the presence or absence of cognitive impairment or cognitive decline in the human and (II) a second index value indicating the degree of progression of cognitive impairment or cognitive decline in the human; and a supporting information generating step of generating information that supports determination of cognitive impairment, cognitive decline, or risk of any of them, based on the first index value and the second index value.